Regenerative medicine research at Pfizer. (November 2011)

• Record Type: Journal Article
• Authors: McKernan, Ruth
• Is Part Of: Regenerative medicine. Volume 6(2011)Supplement 6
• Page Start: 62
• Page End: 64
• Publication Date: 2011-11
• Subjects: Cellular therapy -- Periodicals; Stem cells -- Transplantation -- Periodicals; Degeneration (Pathology) -- Treatment -- Periodicals; Regeneration (Biology) -- Periodicals; 611.018
• DOI: 10.2217/rme.11.74
• Languages: English
• ISSNs: 1746-0751

Abstract

Interview with Ruth McKernan Ruth McKernan, Chief Scientific Officer at Pfizer Neusentis talks to Regenerative Medicine about the founding of Pfizer''s regenerative medicine research program and explains what the recent restructure of the Unit will mean for regenerative medicine at Pfizer. Ruth McKernan is Chief Scientific Officer of Pfizer Neusentis. McKernan is a renowned neuroscientist, author of over 120 publications and a visiting Professor at King''s College London. She graduated from the University of London with joint honors in biochemistry and pharmacology and gained her PhD studying the mechanism of action of antidepressant drugs. After 2 years as a researcher at University of California, San Diego she returned to the UK to start a successful career in the pharmaceutical industry. McKernan was instrumental in the creation of Pfizer Regenerative Medicine, hailed by many as the first major foray into the field by big pharma.